Kimberly-Clark (KMB) 10-Q 1 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 25, 2013
Document And Entity Information	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'
Entity Registrant Name	'KIMBERLY CLARK CORP	'
Entity Central Index Key	'0000055785	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	381,638,993

Consolidated_Income_Statement

Consolidated Income Statement (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]	'	'	'	'
Net Sales	$5,262	$5,246	$15,847	$15,756
Cost of products sold	3,457	3,480	10,420	10,531
Gross Profit	1,805	1,766	5,427	5,225
Marketing, research and general expenses	990	988	3,029	3,003
Other (income) and expense, net	8	-5	12	-15
Operating Profit	807	783	2,386	2,237
Interest income	6	4	16	13
Interest expense	-73	-70	-211	-212
Income Before Income Taxes and Equity Interests	740	717	2,191	2,038
Provision for income taxes	-224	-223	-685	-621
Income Before Equity Interests	516	494	1,506	1,417
Share of net income of equity companies	49	43	157	125
Net Income	565	537	1,663	1,542
Net income attributable to noncontrolling interests	-19	-20	-60	-59
Net Income Attributable to Kimberly-Clark Corporation	$546	$517	$1,603	$1,483
Net Income Attributable to Kimberly-Clark Corporation	'	'	'	'
Basic	$1.43	$1.31	$4.16	$3.77
Diluted	$1.42	$1.30	$4.13	$3.73
Cash Dividends Declared	$0.81	$0.74	$2.43	$2.22

Consolidated_Statement_Of_Comp

Consolidated Statement Of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Statement of Other Comprehensive Income [Abstract]	'	'	'	'
Net Income	$565	$537	$1,663	$1,542
Other Comprehensive Income, Net of Tax	'	'	'	'
Unrealized currency translation adjustments	204	141	-387	133
Employee postretirement benefits	-5	-54	84	-46
Other	-19	-10	9	-10
Total Other Comprehensive Income, Net of Tax	180	77	-294	77
Comprehensive Income	745	614	1,369	1,619
Comprehensive income attributable to noncontrolling interests	-32	-27	-59	-70
Comprehensive Income Attributable to Kimberly-Clark Corporation	$713	$587	$1,310	$1,549

Consolidated_Balance_Sheet

Consolidated Balance Sheet (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Current Assets	'	'
Cash and cash equivalents	$1,179	$1,106
Accounts receivable, net	2,502	2,642
Note receivable	396	0
Inventories	2,245	2,348
Other current assets	572	493
Total Current Assets	6,894	6,589
Property, Plant and Equipment, Net	7,871	8,095
Investments in Equity Companies	429	355
Goodwill	3,223	3,337
Other Intangible Assets	257	246
Long-Term Note Receivable	0	395
Other Assets	690	856
TOTAL ASSETS	19,364	19,873
Current Liabilities	'	'
Debt payable within one year	1,087	1,115
Trade accounts payable	2,360	2,443
Accrued expenses	2,023	2,244
Dividends payable	310	289
Total Current Liabilities	5,780	6,091
Long-Term Debt	5,388	5,070
Noncurrent Employee Benefits	1,725	1,992
Other Liabilities	946	884
Redeemable Preferred and Common Securities of Subsidiaries	549	549
Stockholders' Equity	'	'
Kimberly-Clark Corporation	4,667	4,985
Noncontrolling interests	309	302
Total Stockholders' Equity	4,976	5,287
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$19,364	$19,873

Consolidated_Cash_Flow_Stateme

Consolidated Cash Flow Statement (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating Activities	'	'
Net Income	$1,663	$1,542
Depreciation and amortization	641	642
Asset impairments	42	0
Stock-based compensation	73	57
Deferred income taxes	128	320
Net (gains) losses on asset dispositions	0	15
Equity companies' earnings in excess of dividends paid	-75	-53
(Increase) decrease in operating working capital	-259	-335
Postretirement benefits	-135	-11
Other	17	-8
Cash Provided by Operations	2,095	2,169
Investing Activities	'	'
Capital spending	-697	-763
Acquisitions of businesses	-32	-5
Proceeds from dispositions of property	113	6
Proceeds from sales of investments	16	14
Investments in time deposits	-46	-61
Maturities of time deposits	66	78
Other	-10	2
Cash Used for Investing	-590	-729
Financing Activities	'	'
Cash dividends paid	-913	-859
Change in short-term borrowings	22	464
Debt proceeds	889	315
Debt repayments	-542	-471
Cash paid on redeemable preferred securities of subsidiary	-21	-21
Proceeds from exercise of stock options	164	523
Acquisitions of common stock for the treasury	-959	-962
Other	7	25
Cash Used for Financing	-1,353	-986
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-79	31
Increase (Decrease) in Cash and Cash Equivalents	73	485
Cash and Cash Equivalents - Beginning of Year	1,106	764
Cash and Cash Equivalents - End of Period	$1,179	$1,249

Accounting_Policies

Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Accounting Policies	'
	Accounting Policies
	Basis of Presentation
	The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form  10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair presentation of the results for the periods presented have been reflected. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted.
	For further information, refer to the Consolidated Financial Statements and footnotes included in our Annual Report on Form  10-K for the year ended December 31, 2012. The terms "Corporation," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries.
	Annual Goodwill Impairment Test
	Goodwill is tested for impairment annually and whenever events and circumstances indicate that impairment may have occurred. During the third quarter of 2013, we changed the measurement date of our annual goodwill impairment test from the beginning of the fourth quarter to the beginning of the third quarter. This change did not result in the delay, acceleration or avoidance of an impairment charge. We believe this timing is preferable as it better aligns the goodwill impairment test with our strategic business planning process, which is a key component of the goodwill impairment test. The change was applied prospectively, as retrospective application would have been impractical because we are unable to objectively select assumptions that would have been used in previous periods without the benefit of hindsight. We have completed the required annual testing of goodwill for impairment for all reporting units and have determined that goodwill is not impaired.
	Highly Inflationary Accounting for Venezuelan Operations
	We account for our operations in Venezuela using highly inflationary accounting. On February 13, 2013, the Venezuelan government announced a devaluation of the Central Bank of Venezuela ("Central Bank") regulated currency exchange system rate to 6.3 bolivars per U.S. dollar and the elimination of the SITME rate. As a result of the devaluation, we recorded a $26 after tax charge ($36 pre-tax) related to the remeasurement of the local currency-denominated balance sheet to the new exchange rate in the quarter ended March 31, 2013. Prior to devaluation, we used the Central Bank SITME rate of 5.4 bolivars per U.S. dollar to measure K-C Venezuela's bolivar-denominated transactions into U.S. dollars. The $36 pre-tax charge is reflected in the Consolidated Income Statement in other (income) and expense, net for the nine months ended September 30, 2013. In the Consolidated Cash Flow Statement, this non-cash charge is included in other in cash provided by operations.
	At September 30, 2013, K-C Venezuela had a bolivar-denominated net monetary asset position of $285 and our net investment in K-C Venezuela was $414, both valued at 6.3 bolivars per U.S. dollar. Net sales of K-C Venezuela represented approximately 2 percent of consolidated net sales for the three and nine month periods ended September 30, 2013 and 2012.

European_Strategic_Changes

European Strategic Changes (European Strategic Changes [Member])	9 Months Ended
	Sep. 30, 2013
European Strategic Changes [Member]	'
Restructuring Cost and Reserve	'
European Strategic Changes	'
	European Strategic Changes
	In October 2012, we approved strategic changes related to our Western and Central European consumer and professional businesses to focus our resources and investments on stronger market positions and growth opportunities. We have exited the diaper category in that region, with the exception of the Italian market, and divested or exited some lower-margin businesses, mostly in consumer tissue, in certain markets. The changes primarily affect our consumer businesses, with a modest impact on K-C Professional ("KCP"). The restructuring actions commenced in the fourth quarter of 2012 and are expected to be completed by December 31, 2014. Restructuring actions related to the strategic changes involve the sale or closure of five of our European manufacturing facilities and streamlining our administrative organization.
	The following charges were incurred in connection with the European strategic changes:
		Three Months Ended September 30, 2013				Nine Months Ended September 30, 2013
	Asset impairments	$	22			$	22
	Charges for workforce reductions	(23		)		4
	Asset write-offs	1				13
	Incremental depreciation	3				18
	Benefit from pension curtailment	(1		)		(30		)
	Other exit costs	4				17
	Cost of products sold	6				44
	Charges for workforce reductions and other included in marketing, research and general expenses and other (income) and expense, net	8				23
	Provision for income taxes	(4		)		(15		)
	Net charges	$	10			$	52
	See Note 9 for the charges by segment.
	Through September 30, 2013, cumulative pre-tax charges for the strategic changes were $366 ($294 after tax), including cumulative pre-tax cash charges of $187. Cumulative pre-tax charges by segment were as follows: Personal Care - $243, Consumer Tissue - $88 and K-C Professional - $32.
	The following summarizes the cash charges recorded and reconciles these charges to accrued expenses:
			2013
	Accrued expenses - January 1		$	133
	Charges for workforce reductions and other costs		53
	Cash payments		(132		)
	Currency and other		(9		)
	Accrued expenses - September 30		$	45

Pulp_And_Tissue_Restructuring

Pulp And Tissue Restructuring (Pulp And Tissue Restructuring [Member])	9 Months Ended
	Sep. 30, 2013
Pulp And Tissue Restructuring [Member]	'
Restructuring Cost and Reserve	'
Pulp and Tissue Restructuring	'
	Pulp and Tissue Restructuring Actions
	In 2011 and 2012, we executed pulp and tissue restructuring actions in order to exit our remaining integrated pulp manufacturing operations and improve the underlying profitability and return on invested capital of our consumer tissue and KCP businesses. These actions involved the streamlining, sale or closure of seven of our manufacturing facilities around the world. In conjunction with these actions, we exited certain non-strategic products, primarily non-branded offerings, and transferred some production to lower-cost facilities in order to improve overall profitability and returns. The actions were substantially complete at December 31, 2012.
	During the three months ended September 30, 2012, charges of $30 and $1 were recorded in cost of products sold and marketing, research and general expenses, respectively, for the restructuring actions. A related benefit of $15 was recorded in provision for income taxes. On a geographic basis, charges of $10 and $22 and a credit of $1 were recorded in the United States, Australia and other countries, respectively.
	During the nine months ended September 30, 2012, charges of $83 and $2 were recorded in cost of products sold and marketing, research and general expenses, respectively, for the restructuring actions. A related benefit of $29 was recorded in provision for income taxes. On a geographic basis, $58 and $27 of the charges were recorded in the United States and Australia, respectively.
	See Note 9 for the charges by segment.

Fair_Value_Information

Fair Value Information	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Information	'
	Fair Value Information
	The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are:
	Level 1 – Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities.
	Level 2 – Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly.
	Level 3 – Prices or valuations that require inputs that are significant to the valuation and are unobservable.
	A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	During the nine months ended September 30, 2013 and for the full year 2012, there were no significant transfers among level 1, 2, or 3 fair value determinations.
	Set forth below are the assets and liabilities that are measured on a recurring basis at fair value and the inputs used to develop those fair value measurements.
		September 30, 2013				Fair Value Measurements
						Level 1				Level 2				Level 3
	Assets
	Company-owned life insurance (“COLI”)	$	53			$	—			$	53			$	—
	Available-for-sale securities	20				20				—				—
	Derivatives	69				—				69				—
	Total	$	142			$	20			$	122			$	—
	Liabilities
	Derivatives	$	57			$	—			$	57			$	—
		December 31, 2012				Fair Value Measurements
						Level 1				Level 2				Level 3
	Assets
	COLI	$	49			$	—			$	49			$	—
	Available-for-sale securities	17				17				—				—
	Derivatives	61				—				61				—
	Total	$	127			$	17			$	110			$	—
	Liabilities
	Derivatives	$	63			$	—			$	63			$	—
	The COLI policies are a source of funding primarily for our nonqualified employee benefits and are included in other assets. Available-for-sale securities are included in other assets. See Note 8 for information on the classification of derivatives in the Consolidated Balance Sheet.
	Level 1 Fair Values - The fair values of certain available-for-sale securities are based on quoted market prices in active markets for identical assets.
	Level 2 Fair Values - The fair value of the COLI policies is derived from investments in a mix of money market, fixed income and equity funds managed by unrelated fund managers. The fair values of derivatives used to manage interest rate risk and commodity price risk are based on LIBOR rates and interest rate swap curves and NYMEX price quotations, respectively. The fair value of hedging instruments used to manage foreign currency risk is based on published quotations of spot currency rates and forward points, which are converted into implied forward currency rates. Additional information on our use of derivative instruments is contained in Note 8.
	The following table includes the fair value of our financial instruments for which disclosure of fair value is required:
		Fair Value Hierarchy Level		Carrying Amount				Estimated Fair Value				Carrying Amount				Estimated Fair Value
				September 30, 2013								December 31, 2012
	Assets
	Cash and cash equivalents(a)	1		$	1,179			$	1,179			$	1,106			$	1,106
	Time deposits(b)	1		202				202				224				224
	Note receivable(c)	3		396				397				395				392
	Liabilities and redeemable securities of subsidiaries
	Short-term debt(d)	2		374				374				359				359
	Monetization loan(c)	3		397				398				397				400
	Long-term debt(e)	2		5,704				6,361				5,429				6,527
	Redeemable preferred securities of subsidiary(c)	3		506				532				506				543
	Redeemable common securities of subsidiary(f)	3		43				43				43				43
	(a)	Cash equivalents are comprised of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.
	(b)	Time deposits are comprised of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in other current assets or other assets in the Consolidated Balance Sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value.
	(c)	The note, monetization loan and redeemable preferred securities of subsidiary are not traded in active markets. Accordingly, their fair values were calculated using a floating rate pricing model that compared the stated spread to the fair value spread to determine the price at which each of the financial instruments should trade. The model used the following inputs to calculate fair values: face value, current LIBOR rate, unobservable fair value credit spread, stated spread, maturity date and interest payment dates.
	(d)	Short-term debt is comprised of U.S. commercial paper and other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
	(e)	Long-term debt includes the current portion of these debt instruments and excludes the monetization loan. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.
	(f)	The fair value of the redeemable common securities of subsidiary was based on various inputs, including an independent third-party appraisal, adjusted for current market conditions.

Employee_Postretirement_Benefi

Employee Postretirement Benefits	9 Months Ended
	Sep. 30, 2013
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'
Employee Postretirement Benefits	'
	Employee Postretirement Benefits
	The table below presents net periodic benefit cost information for defined benefit plans and other postretirement benefit plans:
		Pension Benefits						Other Benefits
		Three Months Ended September 30
		2013			2012			2013		2012
	Service cost	$	13		$	10		$	4	$	3
	Interest cost	63			69			9		9
	Expected return on plan assets	(82		)	(82		)	—		—
	Recognized net actuarial loss	28			27			2		—
	Curtailment (see Note 2)	(1		)	—			—		—
	Other	2			3			—		1
	Net periodic benefit cost	$	23		$	27		$	15	$	13
		Pension Benefits						Other Benefits
		Nine Months Ended September 30
		2013			2012			2013		2012
	Service cost	$	40		$	34		$	12	$	11
	Interest cost	191			209			25		28
	Expected return on plan assets	(246		)	(247		)	—		—
	Recognized net actuarial loss	91			82			2		—
	Curtailment (see Note 2)	(30		)	—			—		—
	Other	(1		)	20			—		—
	Net periodic benefit cost	$	45		$	98		$	39	$	39
	For the nine months ended September 30, 2013 and 2012, we made cash contributions of $175 and $95, respectively, to our pension trusts. We expect to contribute approximately $200 to our defined benefit pension plans for the full year 2013.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Earnings Per Share ("EPS")
	There are no adjustments required to be made to net income for purposes of computing basic and diluted EPS. The average number of common shares outstanding is reconciled to those used in the basic and diluted EPS computations as follows:
		Three Months Ended		Nine Months Ended
		30-Sep		30-Sep
	(Millions of shares)	2013	2012	2013	2012
	Basic	382.8	393.9	384.9	393.8
	Dilutive effect of stock options	1.4	1.7	1.6	1.9
	Dilutive effect of restricted share and restricted share unit awards	1.6	1.1	1.5	1.4
	Diluted	385.8	396.7	388	397.1
	Outstanding options during the three and nine month periods ended September 30, 2013 of 1.8 million and 0.9 million, respectively, were not included in the computation of diluted EPS mainly because the exercise prices of the options were greater than the average market price of the common shares during the periods. There were no significant outstanding options excluded from the computation of diluted EPS during the three and nine month periods ended September 30, 2012.
	The number of common shares outstanding as of September 30, 2013 and 2012 was 382.1 million and 392.3 million, respectively.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	Stockholders' Equity
	Set forth below is a reconciliation for the nine months ended September 30, 2013 of the carrying amount of total stockholders' equity from the beginning of the period to the end of the period. In addition, the reconciliation displays the amount of net income allocable to redeemable securities of subsidiaries.
						Stockholders' Equity Attributable to
			Comprehensive Income			The Corporation				Noncontrolling Interests				Redeemable Securities of Subsidiaries
	Balance at December 31, 2012					$	4,985			$	302			$	549
	Comprehensive Income
	Net Income		$	1,663		1,603				37				23
	Other comprehensive income, net of tax
	Unrealized translation		(387		)	(386		)		(1		)		—
	Employee postretirement benefits		84			84				—				—
	Other		9			9				—				—
	Total Comprehensive Income		$	1,369
	Stock-based awards exercised or vested					163				—				—
	Recognition of stock-based compensation					73				—				—
	Income tax benefits on stock-based compensation					30				—				—
	Shares repurchased					(963		)		—				—
	Dividends declared					(934		)		(27		)		—
	Other					3				(1		)		(2		)
	Return of redeemable securities of subsidiaries					—				(1		)		(21		)
	Balance at September 30, 2013					$	4,667			$	309			$	549
	In the nine months ended September 30, 2013, we repurchased 10.0 million shares at a total cost of $950.
	Net unrealized currency gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries, except those in highly inflationary economies, are recorded in Accumulated Other Comprehensive Income ("AOCI"). For these operations, changes in exchange rates generally do not affect cash flows; therefore, unrealized translation is recorded in AOCI rather than net income. Upon sale or substantially complete liquidation of any of these subsidiaries, the applicable unrealized translation would be removed from AOCI and reported as part of the gain or loss on the sale or liquidation.
	Also included in unrealized translation are the effects of foreign exchange rate changes on intercompany balances of a long-term investment nature and transactions designated as hedges of net foreign investments.
	The change in net unrealized currency translation for the nine months ended September 30, 2013 was primarily due to a strengthening of the U.S. dollar against the Australian dollar, as well as most other foreign currencies.
	The changes in the components of AOCI attributable to Kimberly-Clark, net of tax, are as follows:
			Unrealized Translation			Defined Benefit Pension Plans				Other Postretirement Benefit Plans				Cash Flow Hedges and Other
	Balance as of December 31, 2011		$	(221	)	$	(1,578	)		$	(31	)		$	(36	)
	Other comprehensive income/(loss) before reclassifications		124			(101		)		(9		)		(10		)
	(Income)/loss reclassified from AOCI		—			62			(a)	—			(a)	—
	Net current period other comprehensive income/(loss)		124			(39		)		(9		)		(10		)
	Balance as of September 30, 2012		$	(97	)	$	(1,617	)		$	(40	)		$	(46	)
	Balance as of December 31, 2012		$	(26	)	$	(1,928	)		$	(53	)		$	(52	)
	Other comprehensive income/(loss) before reclassifications		(386		)	57				1				17
	(Income)/loss reclassified from AOCI		—			28			(a)	(2		)	(a)	(8		)
	Net current period other comprehensive income/(loss)		(386		)	85				(1		)		9
	Balance as of September 30, 2013		$	(412	)	$	(1,843	)		$	(54	)		$	(43	)
	(a)	Included in computation of net periodic pension and postretirement benefits costs (see Note 5).

Objectives_And_Strategies_For_

Objectives And Strategies For Using Derivatives	9 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Objectives And Strategies For Using Derivatives	'
	Objectives and Strategies for Using Derivatives
	As a multinational enterprise, we are exposed to financial risks, such as changes in foreign currency exchange rates, interest rates, and commodity prices. We employ a number of practices to manage these risks, including operating and financing activities and, where appropriate, the use of derivative instruments. We enter into derivative instruments to hedge a portion of forecasted cash flows denominated in foreign currencies for non-U.S. operations' purchases of pulp, which are priced in U.S. dollars, and imports of intercompany finished goods and work-in-process priced predominantly in U.S. dollars and euros. The derivative instruments used to manage these exposures are designated and qualify as cash flow hedges. The foreign currency exposure on certain non-functional currency denominated monetary assets and liabilities, primarily intercompany loans and accounts payable, is hedged with primarily undesignated derivative instruments. Interest rate risk is managed using a portfolio of variable- and fixed-rate debt composed of short- and long-term instruments. Interest rate swap contracts may be used to facilitate the maintenance of the desired ratio of variable- and fixed-rate debt and are designated and qualify as fair value hedges. From time to time, we also hedge the anticipated issuance of fixed-rate debt, using forward-starting swaps or treasury locks, and these contracts are designated as cash flow hedges. We use derivative instruments, such as forward swap contracts, to hedge a limited portion of our exposure to market risk arising from changes in prices of certain commodities. These derivatives are designated as cash flow hedges of specific quantities of the underlying commodity expected to be purchased in future months. Translation adjustments result from translating foreign entities' financial statements into U.S. dollars from their functional currencies. The risk to any particular entity's net assets is reduced to the extent that the entity is financed with local currency borrowing. Translation exposure, which results from changes in translation rates between functional currencies and the U.S. dollar, generally is not hedged. However, consistent with other years, a portion of our net investment in our Mexican affiliate has been hedged. At September 30, 2013, we had in place net investment hedges of $73 for a portion of our investment in our Mexican affiliate.
	Set forth below is a summary of the total designated and undesignated fair values of our derivative instruments:
		Assets				Liabilities
		September 30,		December 31,		September 30,		December 31,
		2013		2012		2013		2012
	Foreign currency exchange contracts	$	52	$	52	$	55	$	17
	Interest rate contracts	16		7		1		43
	Commodity price contracts	1		2		1		3
	Total	$	69	$	61	$	57	$	63
	The derivative assets are included in the Consolidated Balance Sheet in other current assets and other assets, as appropriate. The derivative liabilities are included in the Consolidated Balance Sheet in accrued expenses and other liabilities, as appropriate.
	Effect of Derivative Instruments on Results of Operations and Other Comprehensive Income
	Derivative instruments that are designated and qualify as fair value hedges are predominantly used to manage interest rate risk. The fair values of these derivative instruments are recorded as an asset or liability, as appropriate, with the offset recorded in current earnings. The offset to the change in fair values of the related hedged items also is recorded in current earnings. Any realized gain or loss on the derivatives that hedge interest rate risk is amortized to interest expense over the life of the related debt. At September 30, 2013, the aggregate notional values of outstanding interest rate contracts designated as fair value hedges were $250. Fair value hedges resulted in no significant ineffectiveness in the nine months ended September 30, 2013 and 2012. For the nine month periods ended September 30, 2013 and 2012, gains or losses recognized in interest expense for interest rate swaps were not significant. For the nine month periods ended September 30, 2013 and 2012, no gain or loss was recognized in earnings as a result of a hedged firm commitment no longer qualifying as a fair value hedge.
	For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative instrument is initially recorded in AOCI, net of related income taxes, and recognized in earnings in the same period that the hedged exposure affects earnings. As of September 30, 2013, outstanding commodity forward contracts were in place to hedge a limited portion of our estimated requirements of the related underlying commodities in the remainder of 2013 and future periods. As of September 30, 2013, the aggregate notional values of outstanding foreign exchange and interest rate derivative contracts designated as cash flow hedges were $1 billion and $200, respectively. Cash flow hedges resulted in no significant ineffectiveness for the nine months ended September 30, 2013 and 2012. For the nine months ended September 30, 2013 and 2012, no gains or losses were reclassified into earnings as a result of the discontinuance of cash flow hedges due to the original forecasted transaction no longer being probable of occurring. At September 30, 2013, amounts to be reclassified from AOCI during the next twelve months are not expected to be material. The maximum maturity of cash flow hedges in place at September 30, 2013 is October 2015.
	Undesignated foreign exchange hedging instrument gains or losses are immediately recognized in other (income) and expense, net. Gains of $77 and $30 were recorded in the three month periods ended September 30, 2013 and 2012, respectively. Losses of $65 and gains of $31 were recorded in the nine month periods ended September 30, 2013 and 2012, respectively. The effect on earnings from the use of these non-designated derivatives is substantially neutralized by the transactional gains and losses recorded on the underlying assets and liabilities. At September 30, 2013, the notional amount of these undesignated derivative instruments was $2.6 billion.

Description_Of_Business_Segmen

Description Of Business Segments	9 Months Ended
	Sep. 30, 2013
Description of Business Segments	'
Description Of Business Segments	'
	Description of Business Segments
	We are organized into operating segments based on product groupings. These operating segments have been aggregated into four reportable global business segments: Personal Care, Consumer Tissue, KCP and Health Care. The reportable segments were determined in accordance with how our executive managers develop and execute global strategies to drive growth and profitability. These strategies include global plans for branding and product positioning, technology, research and development programs, cost reductions including supply chain management, and capacity and capital investments for each of these businesses. Segment management is evaluated on several factors, including operating profit. Segment operating profit excludes other (income) and expense, net and income and expense not associated with the business segments, including the charges related to the European strategic changes and the pulp and tissue restructuring actions described in Notes 2 and 3, respectively.
	The principal sources of revenue in each global business segment are described below:
	•	Personal Care brands offer parents a trusted partner in caring for their families and deliver confidence, protection and discretion to adults through a wide variety of innovative solutions and products such as disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and other related products. Products in this segment are sold under the Huggies, Pull-Ups, Little Swimmers, GoodNites, Kotex, Depend, Plenitud, Poise and other brand names.
	•	Consumer Tissue offers a wide variety of innovative solutions and trusted brands that touch and improve people's lives every day.  Products in this segment include facial and bathroom tissue, paper towels, napkins and related products, and are sold under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Hakle, Page and other brand names.
	•	K‑C Professional helps transform workplaces for employees and patrons, making them healthier, safer and more productive, through a range of solutions and supporting products such as apparel, wipers, soaps, sanitizers, tissues and towels.  Key brands in this segment include Kleenex, Scott, WypAll, Kimtech and Jackson Safety.
	•	Health Care provides essentials that help restore patients to better health and improve the quality of patients' lives. This segment offers surgical and infection prevention products for the operating room, and a portfolio of innovative medical devices focused on pain management, respiratory and digestive health. This business is a global leader in education to prevent healthcare-associated infections. Products are sold primarily under the Kimberly-Clark and ON-Q brand names.
	The following schedules present information concerning consolidated operations by business segment:
			Three Months Ended September 30										Nine Months Ended September 30
			2013				2012				Change		2013			2012			Change
	NET SALES
	Personal Care		$	2,383			$	2,414			-1.3	%	$	7,170		$	7,196		-0.4	%
	Consumer Tissue		1,626				1,605				1.3	%	4,969			4,852			2.4	%
	K-C Professional		843				822				2.6	%	2,477			2,458			0.8	%
	Health Care		403				396				1.8	%	1,201			1,212			-0.9	%
	Corporate & Other		7				9				N.M.		30			38			N.M.
	TOTAL NET SALES		$	5,262			$	5,246			0.3	%	$	15,847		$	15,756		0.6	%
	OPERATING PROFIT
	Personal Care		$	427			$	436			-2.1	%	$	1,300		$	1,241		4.8	%
	Consumer Tissue		233				216				7.9	%	713			652			9.4	%
	K-C Professional		155				144				7.6	%	459			407			12.8	%
	Health Care		70				59				18.6	%	168			168			—
	Corporate & Other(a)		(70		)		(77		)		N.M.		(242		)	(246		)	N.M.
	Other (income) and expense, net		8				(5		)		N.M.		12			(15		)	N.M.
	TOTAL OPERATING PROFIT		$	807			$	783			3.1	%	$	2,386		$	2,237		6.7	%
	N.M. - Not meaningful
	(a)	Corporate & Other includes the following charges:
		European Strategic Changes								Pulp & Tissue Restructuring Actions
		Three Months Ended September 30, 2013				Nine Months Ended September 30, 2013				Three Months Ended September 30, 2012			Nine Months Ended September 30, 2012
	Personal Care	$	1			$	30			$	—		$	—
	Consumer Tissue	7				22				31			80
	K-C Professional	3				12				—			5
	Total	$	11			$	64			$	31		$	85

Supplemental_Balance_Sheet_Dat

Supplemental Balance Sheet Data (Notes)	9 Months Ended
	Sep. 30, 2013
Statement of Financial Position [Abstract]	'
Additional Financial Information Disclosure	'
	Supplemental Balance Sheet Data
	The following schedule presents a summary of inventories by major class:
			September 30, 2013									December 31, 2012
			LIFO				Non-LIFO		Total			LIFO			Non-LIFO		Total
	At the lower of cost, determined on the FIFO or weighted-average cost methods, or market
	Raw materials		$	141			$	329	$	470		$	148		$	346	$	494
	Work in process		207				102		309			194			135		329
	Finished goods		634				743		1,377			656			786		1,442
	Supplies and other		—				329		329			—			314		314
			982				1,503		2,485			998			1,581		2,579
	Excess of FIFO or weighted-average cost over LIFO cost		(240		)		—		(240		)	(231		)	—		(231		)
	Total		$	742			$	1,503	$	2,245		$	767		$	1,581	$	2,348
	We use the LIFO method of valuing inventory for financial reporting purposes for most U.S. inventories. Interim LIFO calculations are based on management's estimates of expected year-end inventory levels and costs. An actual valuation of inventory under the LIFO method is made at the end of each year based on the inventory levels and costs at that time.
	The following schedule presents a summary of property, plant and equipment, net:
		September 30, 2013				December 31, 2012
	Land	$	197			$	199
	Buildings	2,780				2,732
	Machinery and equipment	14,176				13,993
	Construction in progress	402				732
		17,555				17,656
	Less accumulated depreciation	(9,684		)		(9,561		)
	Total	$	7,871			$	8,095

Accounting_Policies_Accounting

Accounting Policies Accounting (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	Accounting Policies
	Basis of Presentation
	The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form  10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair presentation of the results for the periods presented have been reflected. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted.
	For further information, refer to the Consolidated Financial Statements and footnotes included in our Annual Report on Form  10-K for the year ended December 31, 2012. The terms "Corporation," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries.
	Annual Goodwill Impairment Test
	Goodwill is tested for impairment annually and whenever events and circumstances indicate that impairment may have occurred. During the third quarter of 2013, we changed the measurement date of our annual goodwill impairment test from the beginning of the fourth quarter to the beginning of the third quarter. This change did not result in the delay, acceleration or avoidance of an impairment charge. We believe this timing is preferable as it better aligns the goodwill impairment test with our strategic business planning process, which is a key component of the goodwill impairment test. The change was applied prospectively, as retrospective application would have been impractical because we are unable to objectively select assumptions that would have been used in previous periods without the benefit of hindsight. We have completed the required annual testing of goodwill for impairment for all reporting units and have determined that goodwill is not impaired.
	Highly Inflationary Accounting for Venezuelan Operations
	We account for our operations in Venezuela using highly inflationary accounting. On February 13, 2013, the Venezuelan government announced a devaluation of the Central Bank of Venezuela ("Central Bank") regulated currency exchange system rate to 6.3 bolivars per U.S. dollar and the elimination of the SITME rate. As a result of the devaluation, we recorded a $26 after tax charge ($36 pre-tax) related to the remeasurement of the local currency-denominated balance sheet to the new exchange rate in the quarter ended March 31, 2013. Prior to devaluation, we used the Central Bank SITME rate of 5.4 bolivars per U.S. dollar to measure K-C Venezuela's bolivar-denominated transactions into U.S. dollars. The $36 pre-tax charge is reflected in the Consolidated Income Statement in other (income) and expense, net for the nine months ended September 30, 2013. In the Consolidated Cash Flow Statement, this non-cash charge is included in other in cash provided by operations.
	At September 30, 2013, K-C Venezuela had a bolivar-denominated net monetary asset position of $285 and our net investment in K-C Venezuela was $414, both valued at 6.3 bolivars per U.S. dollar. Net sales of K-C Venezuela represented approximately 2 percent of consolidated net sales for the three and nine month periods ended September 30, 2013 and 2012.

Fair_Value_Information_Policy

Fair Value Information (Policy)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Level Measurements Policy	'
	The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are:
	Level 1 – Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities.
	Level 2 – Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly.
	Level 3 – Prices or valuations that require inputs that are significant to the valuation and are unobservable.
	A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Supplemental_Balance_Sheet_Dat1

Supplemental Balance Sheet Data (Policies)	9 Months Ended
	Sep. 30, 2013
Statement of Financial Position [Abstract]	'
Inventory Policy	'
	We use the LIFO method of valuing inventory for financial reporting purposes for most U.S. inventories. Interim LIFO calculations are based on management's estimates of expected year-end inventory levels and costs. An actual valuation of inventory under the LIFO method is made at the end of each year based on the inventory levels and costs at that time.

European_Strategic_Changes_Tab

European Strategic Changes (Tables) (European Strategic Changes [Member])	9 Months Ended
	Sep. 30, 2013
European Strategic Changes [Member]	'
Restructuring Cost and Reserve	'
Charges Incurred in Connection with Restructuring	'
		Three Months Ended September 30, 2013				Nine Months Ended September 30, 2013
	Asset impairments	$	22			$	22
	Charges for workforce reductions	(23		)		4
	Asset write-offs	1				13
	Incremental depreciation	3				18
	Benefit from pension curtailment	(1		)		(30		)
	Other exit costs	4				17
	Cost of products sold	6				44
	Charges for workforce reductions and other included in marketing, research and general expenses and other (income) and expense, net	8				23
	Provision for income taxes	(4		)		(15		)
	Net charges	$	10			$	52
Schedule of Cash Charges Reconciled to Accrued Expenses	'
			2013
	Accrued expenses - January 1		$	133
	Charges for workforce reductions and other costs		53
	Cash payments		(132		)
	Currency and other		(9		)
	Accrued expenses - September 30		$	45

Fair_Value_Information_Tables

Fair Value Information (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Assets And Liabilities Measured On A Recurring Basis	'
	Set forth below are the assets and liabilities that are measured on a recurring basis at fair value and the inputs used to develop those fair value measurements.
		September 30, 2013				Fair Value Measurements
						Level 1				Level 2				Level 3
	Assets
	Company-owned life insurance (“COLI”)	$	53			$	—			$	53			$	—
	Available-for-sale securities	20				20				—				—
	Derivatives	69				—				69				—
	Total	$	142			$	20			$	122			$	—
	Liabilities
	Derivatives	$	57			$	—			$	57			$	—
		December 31, 2012				Fair Value Measurements
						Level 1				Level 2				Level 3
	Assets
	COLI	$	49			$	—			$	49			$	—
	Available-for-sale securities	17				17				—				—
	Derivatives	61				—				61				—
	Total	$	127			$	17			$	110			$	—
	Liabilities
	Derivatives	$	63			$	—			$	63			$	—
Fair Value, by Balance Sheet Grouping	'
	The following table includes the fair value of our financial instruments for which disclosure of fair value is required:
		Fair Value Hierarchy Level		Carrying Amount				Estimated Fair Value				Carrying Amount				Estimated Fair Value
				September 30, 2013								December 31, 2012
	Assets
	Cash and cash equivalents(a)	1		$	1,179			$	1,179			$	1,106			$	1,106
	Time deposits(b)	1		202				202				224				224
	Note receivable(c)	3		396				397				395				392
	Liabilities and redeemable securities of subsidiaries
	Short-term debt(d)	2		374				374				359				359
	Monetization loan(c)	3		397				398				397				400
	Long-term debt(e)	2		5,704				6,361				5,429				6,527
	Redeemable preferred securities of subsidiary(c)	3		506				532				506				543
	Redeemable common securities of subsidiary(f)	3		43				43				43				43
	(a)	Cash equivalents are comprised of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.
	(b)	Time deposits are comprised of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in other current assets or other assets in the Consolidated Balance Sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value.
	(c)	The note, monetization loan and redeemable preferred securities of subsidiary are not traded in active markets. Accordingly, their fair values were calculated using a floating rate pricing model that compared the stated spread to the fair value spread to determine the price at which each of the financial instruments should trade. The model used the following inputs to calculate fair values: face value, current LIBOR rate, unobservable fair value credit spread, stated spread, maturity date and interest payment dates.
	(d)	Short-term debt is comprised of U.S. commercial paper and other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
	(e)	Long-term debt includes the current portion of these debt instruments and excludes the monetization loan. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.
	(f)	The fair value of the redeemable common securities of subsidiary was based on various inputs, including an independent third-party appraisal, adjusted for current market conditions.

Employee_Postretirement_Benefi1

Employee Postretirement Benefits (Tables)	9 Months Ended
	Sep. 30, 2013
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'
Components of net periodic benefit cost	'
	The table below presents net periodic benefit cost information for defined benefit plans and other postretirement benefit plans:
		Pension Benefits						Other Benefits
		Three Months Ended September 30
		2013			2012			2013		2012
	Service cost	$	13		$	10		$	4	$	3
	Interest cost	63			69			9		9
	Expected return on plan assets	(82		)	(82		)	—		—
	Recognized net actuarial loss	28			27			2		—
	Curtailment (see Note 2)	(1		)	—			—		—
	Other	2			3			—		1
	Net periodic benefit cost	$	23		$	27		$	15	$	13
		Pension Benefits						Other Benefits
		Nine Months Ended September 30
		2013			2012			2013		2012
	Service cost	$	40		$	34		$	12	$	11
	Interest cost	191			209			25		28
	Expected return on plan assets	(246		)	(247		)	—		—
	Recognized net actuarial loss	91			82			2		—
	Curtailment (see Note 2)	(30		)	—			—		—
	Other	(1		)	20			—		—
	Net periodic benefit cost	$	45		$	98		$	39	$	39

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Average Common Shares Outstanding Basic and Diluted	'
		Three Months Ended		Nine Months Ended
		30-Sep		30-Sep
	(Millions of shares)	2013	2012	2013	2012
	Basic	382.8	393.9	384.9	393.8
	Dilutive effect of stock options	1.4	1.7	1.6	1.9
	Dilutive effect of restricted share and restricted share unit awards	1.6	1.1	1.5	1.4
	Diluted	385.8	396.7	388	397.1

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Components Of Stockholders' Equity	'
						Stockholders' Equity Attributable to
			Comprehensive Income			The Corporation				Noncontrolling Interests				Redeemable Securities of Subsidiaries
	Balance at December 31, 2012					$	4,985			$	302			$	549
	Comprehensive Income
	Net Income		$	1,663		1,603				37				23
	Other comprehensive income, net of tax
	Unrealized translation		(387		)	(386		)		(1		)		—
	Employee postretirement benefits		84			84				—				—
	Other		9			9				—				—
	Total Comprehensive Income		$	1,369
	Stock-based awards exercised or vested					163				—				—
	Recognition of stock-based compensation					73				—				—
	Income tax benefits on stock-based compensation					30				—				—
	Shares repurchased					(963		)		—				—
	Dividends declared					(934		)		(27		)		—
	Other					3				(1		)		(2		)
	Return of redeemable securities of subsidiaries					—				(1		)		(21		)
	Balance at September 30, 2013					$	4,667			$	309			$	549
Schedule of Accumulated Other Comprehensive Income (Loss)	'
			Unrealized Translation			Defined Benefit Pension Plans				Other Postretirement Benefit Plans				Cash Flow Hedges and Other
	Balance as of December 31, 2011		$	(221	)	$	(1,578	)		$	(31	)		$	(36	)
	Other comprehensive income/(loss) before reclassifications		124			(101		)		(9		)		(10		)
	(Income)/loss reclassified from AOCI		—			62			(a)	—			(a)	—
	Net current period other comprehensive income/(loss)		124			(39		)		(9		)		(10		)
	Balance as of September 30, 2012		$	(97	)	$	(1,617	)		$	(40	)		$	(46	)
	Balance as of December 31, 2012		$	(26	)	$	(1,928	)		$	(53	)		$	(52	)
	Other comprehensive income/(loss) before reclassifications		(386		)	57				1				17
	(Income)/loss reclassified from AOCI		—			28			(a)	(2		)	(a)	(8		)
	Net current period other comprehensive income/(loss)		(386		)	85				(1		)		9
	Balance as of September 30, 2013		$	(412	)	$	(1,843	)		$	(54	)		$	(43	)
	(a)	Included in computation of net periodic pension and postretirement benefits costs (see Note 5).

Objectives_And_Strategies_For_1

Objectives And Strategies For Using Derivatives (Tables)	9 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule Of Fair Value Of All Derivative Instruments	'
		Assets				Liabilities
		September 30,		December 31,		September 30,		December 31,
		2013		2012		2013		2012
	Foreign currency exchange contracts	$	52	$	52	$	55	$	17
	Interest rate contracts	16		7		1		43
	Commodity price contracts	1		2		1		3
	Total	$	69	$	61	$	57	$	63

Description_Of_Business_Segmen1

Description Of Business Segments (Tables)	9 Months Ended
	Sep. 30, 2013
Description of Business Segments	'
Information Concerning Consolidated Operations by Business Segment	'
			Three Months Ended September 30										Nine Months Ended September 30
			2013				2012				Change		2013			2012			Change
	NET SALES
	Personal Care		$	2,383			$	2,414			-1.3	%	$	7,170		$	7,196		-0.4	%
	Consumer Tissue		1,626				1,605				1.3	%	4,969			4,852			2.4	%
	K-C Professional		843				822				2.6	%	2,477			2,458			0.8	%
	Health Care		403				396				1.8	%	1,201			1,212			-0.9	%
	Corporate & Other		7				9				N.M.		30			38			N.M.
	TOTAL NET SALES		$	5,262			$	5,246			0.3	%	$	15,847		$	15,756		0.6	%
	OPERATING PROFIT
	Personal Care		$	427			$	436			-2.1	%	$	1,300		$	1,241		4.8	%
	Consumer Tissue		233				216				7.9	%	713			652			9.4	%
	K-C Professional		155				144				7.6	%	459			407			12.8	%
	Health Care		70				59				18.6	%	168			168			—
	Corporate & Other(a)		(70		)		(77		)		N.M.		(242		)	(246		)	N.M.
	Other (income) and expense, net		8				(5		)		N.M.		12			(15		)	N.M.
	TOTAL OPERATING PROFIT		$	807			$	783			3.1	%	$	2,386		$	2,237		6.7	%
	N.M. - Not meaningful
	(a)	Corporate & Other includes the following charges:
		European Strategic Changes								Pulp & Tissue Restructuring Actions
		Three Months Ended September 30, 2013				Nine Months Ended September 30, 2013				Three Months Ended September 30, 2012			Nine Months Ended September 30, 2012
	Personal Care	$	1			$	30			$	—		$	—
	Consumer Tissue	7				22				31			80
	K-C Professional	3				12				—			5
	Total	$	11			$	64			$	31		$	85

Summary_of_Balance_Sheet_Data_

Summary of Balance Sheet Data (Tables)	9 Months Ended
	Sep. 30, 2013
Statement of Financial Position [Abstract]	'
Schedule of Inventory, Current	'
			September 30, 2013									December 31, 2012
			LIFO				Non-LIFO		Total			LIFO			Non-LIFO		Total
	At the lower of cost, determined on the FIFO or weighted-average cost methods, or market
	Raw materials		$	141			$	329	$	470		$	148		$	346	$	494
	Work in process		207				102		309			194			135		329
	Finished goods		634				743		1,377			656			786		1,442
	Supplies and other		—				329		329			—			314		314
			982				1,503		2,485			998			1,581		2,579
	Excess of FIFO or weighted-average cost over LIFO cost		(240		)		—		(240		)	(231		)	—		(231		)
	Total		$	742			$	1,503	$	2,245		$	767		$	1,581	$	2,348
Property, Plant and Equipment	'
		September 30, 2013				December 31, 2012
	Land	$	197			$	199
	Buildings	2,780				2,732
	Machinery and equipment	14,176				13,993
	Construction in progress	402				732
		17,555				17,656
	Less accumulated depreciation	(9,684		)		(9,561		)
	Total	$	7,871			$	8,095

Accounting_Policies_Narrative_

Accounting Policies Narrative (Details) (K-C Venezuela [Member], USD $)	3 Months Ended		9 Months Ended		33 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Feb. 01, 2013
K-C Venezuela [Member]	'	'	'	'	'
Central Bank System Rate	'	'	6.3	'	5.4
Charge for Devaluation Under Highly Inflationary Accounting (after tax)	'	'	$26	'	'
Charge for Devaluation Under Highly Inflationary Accounting	'	'	36	'	'
Bolivar Denominated Monetary Asset Net	285	'	285	'	'
Net Investment Foreign Operations	$414	'	$414	'	'
Portion Of Consolidate Net Sales Earned By Affiliate Percent	2.00%	2.00%	2.00%	2.00%	'

European_Strategic_Changes_Nar

European Strategic Changes - Narrative (Details) (European Strategic Changes [Member], USD $)	3 Months Ended		9 Months Ended		11 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2013		Sep. 30, 2013
Restructuring Cost and Reserve	'		'		'
Restructuring Activities for Manufacturing Facilities	'		5		'
Charges for workforce reductions and other costs	'		'		$366
Restructuring Charges After Tax	10		52		294
Personal Care [Member]	'		'		'
Restructuring Cost and Reserve	'		'		'
Charges for workforce reductions and other costs	1	[1]	30	[1]	243
Consumer Tissue [Member]	'		'		'
Restructuring Cost and Reserve	'		'		'
Charges for workforce reductions and other costs	7	[1]	22	[1]	88
K-C Professional	'		'		'
Restructuring Cost and Reserve	'		'		'
Charges for workforce reductions and other costs	3	[1]	12	[1]	32
Cash charges [Member]	'		'		'
Restructuring Cost and Reserve	'		'		'
Charges for workforce reductions and other costs	'		$53		$187
[1]	Corporate & Other includes the following charges:

European_Strategic_Changes_Cha

European Strategic Changes - Charges Incurred (Details) (European Strategic Changes [Member], USD $)	3 Months Ended	9 Months Ended	11 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
Restructuring Cost and Reserve	'	'	'
Charges for workforce reductions and other costs	'	'	$366
Restructuring Charges After Tax	10	52	294
Cost of Sales [Member]	'	'	'
Restructuring Cost and Reserve	'	'	'
Charges for workforce reductions and other costs	6	44	'
Charges for workforce reductions and other included in marketing, research and general and other (income) and expense, net [Member]	'	'	'
Restructuring Cost and Reserve	'	'	'
Charges for workforce reductions and other costs	8	23	'
Provision for income taxes	'	'	'
Restructuring Cost and Reserve	'	'	'
Charges for workforce reductions and other costs	-4	-15	'
Asset Impairments [Member] | Cost of Sales [Member]	'	'	'
Restructuring Cost and Reserve	'	'	'
Charges for workforce reductions and other costs	22	22	'
Employee Severance [Member] | Cost of Sales [Member]	'	'	'
Restructuring Cost and Reserve	'	'	'
Charges for workforce reductions and other costs	-23	4	'
Asset write-offs | Cost of Sales [Member]	'	'	'
Restructuring Cost and Reserve	'	'	'
Charges for workforce reductions and other costs	1	13	'
Incremental depreciation | Cost of Sales [Member]	'	'	'
Restructuring Cost and Reserve	'	'	'
Charges for workforce reductions and other costs	3	18	'
Benefit from pension curtailment | Cost of Sales [Member]	'	'	'
Restructuring Cost and Reserve	'	'	'
Charges for workforce reductions and other costs	-1	-30	'
Other exit costs | Cost of Sales [Member]	'	'	'
Restructuring Cost and Reserve	'	'	'
Charges for workforce reductions and other costs	$4	$17	'

European_Strategic_Changes_Rec

European Strategic Changes - Reconciliation to Accrued Expenses (Details) (European Strategic Changes [Member], USD $)	9 Months Ended	11 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Accrued Expense Roll Forward	'	'
Accrued expenses - January 1	$133	'
Charges for workforce reductions and other costs	'	366
Cash payments	-132	'
Currency and other	-9	'
Accrued expenses - September 30	45	45
Cash charges [Member]	'	'
Accrued Expense Roll Forward	'	'
Charges for workforce reductions and other costs	$53	$187

Pulp_And_Tissue_Restructuring_

Pulp And Tissue Restructuring (Narrative) (Details) (Pulp And Tissue Restructuring [Member], USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2012		Sep. 30, 2012
Restructuring Cost and Reserve [Line Items]	'		'
Restructuring Activities for Manufacturing Facilities	'		7
Charges for workforce reductions and other costs	($31)	[1]	($85)
UNITED STATES	'		'
Restructuring Cost and Reserve [Line Items]	'		'
Charges for workforce reductions and other costs	-10		-58
AUSTRALIA	'		'
Restructuring Cost and Reserve [Line Items]	'		'
Charges for workforce reductions and other costs	-22		-27
Other Geographic Areas [Member]	'		'
Restructuring Cost and Reserve [Line Items]	'		'
Charges for workforce reductions and other costs	-1		'
Cost of Sales [Member]	'		'
Restructuring Cost and Reserve [Line Items]	'		'
Charges for workforce reductions and other costs	-30		-83
Charges for workforce reductions and other included in marketing, research and general expenses	'		'
Restructuring Cost and Reserve [Line Items]	'		'
Charges for workforce reductions and other costs	-1		-2
Provision for income taxes	'		'
Restructuring Cost and Reserve [Line Items]	'		'
Charges for workforce reductions and other costs	$15		$29
[1]	Corporate & Other includes the following charges:

Fair_Value_Information_Narrati

Fair Value Information (Narrative) (Details) (USD $)	9 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Fair Value Disclosures [Abstract]	'	'
Transfers among fair value determination	$0	$0

Fair_Value_Information_Fair_Va

Fair Value Information (Fair Value Assets And Liabilities Measured On A Recurring Basis) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis	'	'
Company-owned life insurance (bCOLIb)	$53	$49
Available-for-sale securities	20	17
Derivatives	69	61
Total	142	127
Derivatives	57	63
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis	'	'
Company-owned life insurance (bCOLIb)	0	0
Available-for-sale securities	20	17
Derivatives	0	0
Total	20	17
Derivatives	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis	'	'
Company-owned life insurance (bCOLIb)	53	49
Available-for-sale securities	0	0
Derivatives	69	61
Total	122	110
Derivatives	57	63
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis	'	'
Company-owned life insurance (bCOLIb)	0	0
Available-for-sale securities	0	0
Derivatives	0	0
Total	0	0
Derivatives	$0	$0

Fair_Value_Information_Fair_Va1

Fair Value Information (Fair Value Of Financial Instruments) (Details) (USD $)	Sep. 30, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Cash and cash equivalents(a)	$1,179	[1]	$1,106	[1]
Time deposits(b)	202	[2]	224	[2]
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Short-term debt(d)	374	[3]	359	[3]
Long-term debt(e)	5,704	[4]	5,429	[4]
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Note receivable(c)	396	[5]	395	[5]
Monetization loan(c)	397	[5]	397	[5]
Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Cash and cash equivalents(a)	1,179	[1]	1,106	[1]
Time deposits(b)	202	[2]	224	[2]
Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Short-term debt(d)	374	[3]	359	[3]
Long-term debt(e)	6,361	[4]	6,527	[4]
Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Note receivable(c)	397	[5]	392	[5]
Monetization loan(c)	398	[5]	400	[5]
Preferred securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Redeemable preferred securities of subsidiary(c)	506	[5]	506	[5]
Preferred securities [Member] | Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Redeemable preferred securities of subsidiary(c)	532	[5]	543	[5]
common securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Redeemable preferred securities of subsidiary(c)	43	[6]	43	[6]
common securities [Member] | Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Redeemable preferred securities of subsidiary(c)	$43	[6]	$43	[6]
[1]	Cash equivalents are comprised of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.
[2]	Time deposits are comprised of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in other current assets or other assets in the Consolidated Balance Sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value.
[3]	Short-term debt is comprised of U.S. commercial paper and other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
[4]	Long-term debt includes the current portion of these debt instruments and excludes the monetization loan. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.
[5]	The note, monetization loan and redeemable preferred securities of subsidiary are not traded in active markets. Accordingly, their fair values were calculated using a floating rate pricing model that compared the stated spread to the fair value spread to determine the price at which each of the financial instruments should trade. The model used the following inputs to calculate fair values: face value, current LIBOR rate, unobservable fair value credit spread, stated spread, maturity date and interest payment dates.
[6]	The fair value of the redeemable common securities of subsidiary was based on various inputs, including an independent third-party appraisal, adjusted for current market conditions.

Employee_Postretirement_Benefi2

Employee Postretirement Benefits (Narrative) (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'	'
Cash contribution to pension trusts	$175	$95
Defined Benefit Plan, Estimated Future Employer Contributions in Current Fiscal Year	$200	'

Employee_Postretirement_Benefi3

Employee Postretirement Benefits (Benefit Cost Information For Defined Benefit Plans And Other Postretirement Benefit Plans) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Defined Benefit Plans [Member]	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans	'	'	'	'
Service cost	$13	$10	$40	$34
Interest cost	63	69	191	209
Expected return on plan assets	-82	-82	-246	-247
Recognized net actuarial loss	28	27	91	82
Curtailment (see Note 2)	-1	0	-30	0
Other	2	3	-1	20
Net periodic benefit cost	23	27	45	98
Other Postretirement Benefit Plans [Member]	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans	'	'	'	'
Service cost	4	3	12	11
Interest cost	9	9	25	28
Expected return on plan assets	0	0	0	0
Recognized net actuarial loss	2	0	2	0
Curtailment (see Note 2)	0	0	0	0
Other	0	1	0	0
Net periodic benefit cost	$15	$13	$39	$39

Earnings_Per_Share_Narrative_D

Earnings Per Share (Narrative) (Details)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1.8	0.9	'
Common shares outstanding	382.1	382.1	392.3

Earnings_Per_Share_Average_Com

Earnings Per Share (Average Common Shares Outstanding Basic And Diluted) (Details)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'	'	'
Basic	382.8	393.9	384.9	393.8
Dilutive effect of stock options	1.4	1.7	1.6	1.9
Dilutive effect of restricted share and restricted share unit awards	1.6	1.1	1.5	1.4
Diluted	385.8	396.7	388	397.1

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Equity [Abstract]	'
Repurchased shares	10
Stock Repurchased During Period, Value	$950

Stockholders_Equity_Components

Stockholders' Equity (Components Of Stockholders' Equity) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Redeemable Preferred and Common Securities of Subsidiaries	$549	'	$549	'	$549
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Balance at December 31, 2012	'	'	5,287	'	'
Net Income	565	537	1,663	1,542	'
Temporary Equity, Net Income	'	'	23	'	'
Unrealized currency translation adjustments	204	141	-387	133	'
Employee postretirement benefits	-5	-54	84	-46	'
Other	-19	-10	9	-10	'
Comprehensive Income	745	614	1,369	1,619	'
Recognition of stock-based compensation	'	'	-73	-57	'
Balance at September 30, 2013	4,976	'	4,976	'	'
Parent [Member]	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Balance at December 31, 2012	'	'	4,985	'	'
Net Income	'	'	1,603	'	'
Unrealized currency translation adjustments	'	'	-386	124	'
Employee postretirement benefits	'	'	84	'	'
Other	'	'	9	-10	'
Stock-based awards exercised or vested	'	'	163	'	'
Recognition of stock-based compensation	'	'	73	'	'
Income tax benefits on stock-based compensation	'	'	30	'	'
Shares repurchased	'	'	-963	'	'
Dividends declared	'	'	-934	'	'
Other	'	'	3	'	'
Temporary Equity, Return	'	'	0	'	'
Balance at September 30, 2013	4,667	'	4,667	'	'
Noncontrolling Interests [Member]	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Balance at December 31, 2012	'	'	302	'	'
Net Income	'	'	37	'	'
Unrealized currency translation adjustments	'	'	-1	'	'
Employee postretirement benefits	'	'	0	'	'
Other	'	'	0	'	'
Stock-based awards exercised or vested	'	'	0	'	'
Recognition of stock-based compensation	'	'	0	'	'
Income tax benefits on stock-based compensation	'	'	0	'	'
Shares repurchased	'	'	0	'	'
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	'	'	-27	'	'
Other	'	'	-1	'	'
Temporary Equity, Return	'	'	-1	'	'
Balance at September 30, 2013	309	'	309	'	'
Redeemable Securities Of Subsidiaries [Member]	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Temporary Equity, Other Changes	'	'	-2	'	'
Temporary Equity, Return	'	'	($21)	'	'

Stockholders_Equity_Components1

Stockholders' Equity (Components of Accumulated Other Comprehensive Income) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Unrealized translation - Beginning balance	'	'	($26)	($221)
Cash flow hedge and other - Beginning balance	'	'	-52	-36
Other comprehensive income/(loss) before reclassifications	'	'	-386	124
(Income)/loss reclassified from AOCI	'	'	0	0
Other comprehensive income/(loss) before reclassifications	'	'	17	-10
Income/loss reclassified from AOCI	'	'	-8	0
Unrealized currency translation adjustments	204	141	-387	133
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax	5	54	-84	46
Unrealized translation - Ending balance	-412	-97	-412	-97
Cash flow hedge and other - Ending balance	-43	-46	-43	-46
Other	-19	-10	9	-10
Pension Plans, Defined Benefit [Member]	'	'	'	'
Defined benefit and other postretirement benefit plans - Beginning balance	'	'	-1,928	-1,578
Other comprehensive income/(loss) before reclassifications	'	'	57	-101
(Income)/loss reclassified from AOCI	'	'	28	62
Defined benefit and other postretirement benefit plans - Ending balance	-1,843	-1,617	-1,843	-1,617
Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'	'
Defined benefit and other postretirement benefit plans - Beginning balance	'	'	-53	-31
Other comprehensive income/(loss) before reclassifications	'	'	1	-9
(Income)/loss reclassified from AOCI	'	'	-2	0
Defined benefit and other postretirement benefit plans - Ending balance	-54	-40	-54	-40
Parent [Member]	'	'	'	'
Unrealized currency translation adjustments	'	'	-386	124
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax	'	'	-84	'
Other	'	'	9	-10
Parent [Member] | Pension Plans, Defined Benefit [Member]	'	'	'	'
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax	'	'	-85	39
Parent [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'	'
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax	'	'	$1	$9

Objectives_And_Strategies_For_2

Objectives And Strategies For Using Derivatives (Narratives) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'	'	'	'
Notional Amount of Derivative Instruments Designated as Net Investment Hedges	$73,000,000	'	$73,000,000	'
Interest rate swap contracts designated as fair value hedge	250,000,000	'	250,000,000	'
Fair Value Hedge Ineffectiveness is Immaterial Assertion	'	'	'Fair value hedges resulted in no significant ineffectiveness in the nine months ended September 30, 2013 and 2012	'
Gains or losses recognized in Other (income) and expense for foreign exchange contracts, and Interest expense for interest rates swaps were not significant	'	'	'For the nine month periods ended SeptemberB 30, 2013 and 2012, gains or losses recognized in interest expense for interest rate swaps were not significant.	'
Gain from Hedged Firm Commitment Not Qualifying as Fair Value Hedge	'	'	0	0
Notional value of derivative contracts designated as cash flow hedges	1,000,000,000	'	1,000,000,000	'
Interest rate swap contracts designated as cash flow hedge	200,000,000	'	200,000,000	'
Cash Flow Hedge Ineffectiveness is Immaterial	'	'	'Cash flow hedges resulted in no significant ineffectiveness for the nine months ended September 30, 2013 and 2012	'
Gain (Loss) on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net	'	'	0	0
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	77,000,000	30,000,000	-65,000,000	31,000,000
Notional Amount of Foreign Currency Derivatives Intercompany	$2,600,000,000	'	$2,600,000,000	'

Objectives_And_Strategies_For_3

Objectives And Strategies For Using Derivatives Summary of total and undesignated fair values of derivative instruments (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Derivative	'	'
Assets	$69	$61
Liabilities	57	63
Foreign currency exchange contracts	'	'
Derivative	'	'
Assets	52	52
Liabilities	55	17
Interest rate contracts	'	'
Derivative	'	'
Assets	16	7
Liabilities	1	43
Commodity price contracts	'	'
Derivative	'	'
Assets	1	2
Liabilities	$1	$3

Description_Of_Business_Segmen2

Description Of Business Segments (Details) (USD $)

3 Months Ended

9 Months Ended

11 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

11 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

11 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

11 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

European Strategic Changes [Member]

Pulp And Tissue Restructuring [Member]

Pulp And Tissue Restructuring [Member]

Cost of products sold and marketing, research and general expenses [Member]

Cost of products sold and marketing, research and general expenses [Member]

Net Sales [Member]

Net Sales [Member]

Operating Profit [Member]

Operating Profit [Member]

Personal Care [Member]

Personal Care [Member]

Personal Care [Member]

Personal Care [Member]

Personal Care [Member]

Personal Care [Member]

Personal Care [Member]

Personal Care [Member]

Personal Care [Member]

Personal Care [Member]

Personal Care [Member]

Personal Care [Member]

Personal Care [Member]

Consumer Tissue [Member]

Consumer Tissue [Member]

Consumer Tissue [Member]

Consumer Tissue [Member]

Consumer Tissue [Member]

Consumer Tissue [Member]

Consumer Tissue [Member]

Consumer Tissue [Member]

Consumer Tissue [Member]

Consumer Tissue [Member]

Consumer Tissue [Member]

Consumer Tissue [Member]

Consumer Tissue [Member]

K-C Professional

K-C Professional

K-C Professional

K-C Professional

K-C Professional

K-C Professional

K-C Professional

K-C Professional

K-C Professional

K-C Professional

K-C Professional

K-C Professional

K-C Professional

Health Care [Member]

Health Care [Member]

Health Care [Member]

Health Care [Member]

Health Care [Member]

Health Care [Member]

Health Care [Member]

Health Care [Member]

Corporate and Other [Member]

Corporate and Other [Member]

Corporate and Other [Member]

Corporate and Other [Member]

European Strategic Changes [Member]

European Strategic Changes [Member]

European Strategic Changes [Member]

European Strategic Changes [Member]

European Strategic Changes [Member]

Pulp And Tissue Restructuring [Member]

Pulp And Tissue Restructuring [Member]

Net Sales [Member]

Net Sales [Member]

Operating Profit [Member]

Operating Profit [Member]

European Strategic Changes [Member]

European Strategic Changes [Member]

European Strategic Changes [Member]

Pulp And Tissue Restructuring [Member]

Pulp And Tissue Restructuring [Member]

Net Sales [Member]

Net Sales [Member]

Operating Profit [Member]

Operating Profit [Member]

European Strategic Changes [Member]

European Strategic Changes [Member]

European Strategic Changes [Member]

Pulp And Tissue Restructuring [Member]

Pulp And Tissue Restructuring [Member]

Net Sales [Member]

Net Sales [Member]

Operating Profit [Member]

Operating Profit [Member]

Net Sales [Member]

Net Sales [Member]

Operating Profit [Member]

Operating Profit [Member]

Consolidated Net Sales

$5,262

$5,246

$15,847

$15,756

'

'

'

'

'

'

'

'

'

$2,383

$2,414

$7,170

$7,196

'

'

'

'

'

'

'

'

'

$1,626

$1,605

$4,969

$4,852

'

'

'

'

'

'

'

'

'

$843

$822

$2,477

$2,458

'

'

'

'

'

'

'

'

'

$403

$396

$1,201

$1,212

'

'

'

'

$7

$9

$30

$38

Percent change

'

'

'

'

'

'

'

'

'

0.30%

0.58%

3.07%

6.66%

'

'

'

'

'

'

'

'

'

-1.28%

-0.36%

-2.06%

4.75%

'

'

'

'

'

'

'

'

'

1.31%

2.41%

7.87%

9.36%

'

'

'

'

'

'

'

'

'

2.55%

0.77%

7.64%

12.78%

'

'

'

'

1.77%

-0.91%

18.64%

0.00%

'

'

'

'

Total Operating Profit

807

783

2,386

2,237

'

'

'

'

'

'

'

'

'

427

436

1,300

1,241

'

'

'

'

'

'

'

'

'

233

216

713

652

'

'

'

'

'

'

'

'

'

155

144

459

407

'

'

'

'

'

'

'

'

'

70

59

168

168

'

'

'

'

-70

[1]

-77

[1]

-242

[1]

-246

[1]

Other (income) and expense, net

8

-5

12

-15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring charges, before tax

'

'

'

'

$366

$31

[1]

$85

$11

[1]

$64

[1]

'

'

'

'

'

'

'

'

$1

[1]

$30

[1]

$243

$0

[1]

$0

'

'

'

'

'

'

'

'

$7

[1]

$22

[1]

$88

$31

[1]

$80

[1]

'

'

'

'

'

'

'

'

$3

[1]

$12

[1]

$32

$0

[1]

$5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Corporate & Other includes the following charges:

Supplemental_Balance_Sheet_Dat2

Supplemental Balance Sheet Data - Inventory (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Raw materials	$470	$494
Work in process	309	329
Finished goods	1,377	1,442
Supplies and other	329	314
Inventory, Gross	2,485	2,579
Excess of FIFO or weighted-average cost over LIFO cost	-240	-231
Total	2,245	2,348
LIFO [Member]	'	'
Raw materials	141	148
Work in process	207	194
Finished goods	634	656
Supplies and other	0	0
Inventory, Gross	982	998
Excess of FIFO or weighted-average cost over LIFO cost	-240	-231
Total	742	767
Non-LIFO [Member]	'	'
Raw materials	329	346
Work in process	102	135
Finished goods	743	786
Supplies and other	329	314
Inventory, Gross	1,503	1,581
Excess of FIFO or weighted-average cost over LIFO cost	0	0
Total	$1,503	$1,581

Supplemental_Balance_Sheet_Dat3

Supplemental Balance Sheet Data - Property Plant and Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$17,555	$17,656
Less accumulated depreciation	-9,684	-9,561
Total	7,871	8,095
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	197	199
Building [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	2,780	2,732
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	14,176	13,993
Construction in Progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$402	$732